Cancer Research and Biotechnology AG (CRB) is a Swiss preclinical biopharma company developing a novel small molecule treatment for cancer, based in its discovery and innovation on reversing carcinogenesis. Preclinical studies: pancreatic cancer, triple-negative breast cancer, and colon cancer.
Products, services, technology
CRB091, oncology, preclinical. The CRB team has identified a root cause or amplifier of many human cancers. This constitutes the first step towards an effective curative and protective method to treat present and potential patients. Pancreatic cancer, triple-negative breast cancer, and colon cancer.
Cooperation possibilities
Funding: Value derives from knowledge of why and how cancer is started in the body, and developing drugs for a fast-to-market pathway.
Research: Therapeutic agents
Out-licensing
- https://crab.ch
- +41 41 510 01 34
- info@crab.ch
- Kari Sarvanto
Some insights
Developing treatment for advanced deadly cancers with no cure
Invented and patented a well-tolerated treatment to reverse carcinogenesis, aiming to bring it to the patients in record-short time
Surgeons and nurses and others working with the cancer patients daily
Platform innovation to treat degenerative diseases - first cancer
''Daddy is a quack''
